Skip to main content

Table 2 Clinical and laboratory characteristics, and follow-up outcome of the study participants on Pre-ART follow up, JUSH, 2013, N = 588

From: The effect of isoniazid preventive therapy on incidence of tuberculosis among HIV-infected clients under pre-ART care, Jimma, Ethiopia: a retrospective cohort study

Variables

Category

Pre-ART

Total

IPT group No (%)

Non-IPT group No (%)

Past opportunistic infection(n = 587)

Yes

145 (49.49%)

126 (42.86%)

271 (46.17%)

No

148 (50.51%)

168 (57.14%)

316 (53.83%)

WHO clinical stage

Stage I/ II

256 (87.07%)

227 (77.21%)

483 (82.14%)

Stage III/ IV

38 (12.93%)

67 (22.79%)

105 (17.86%)

Functional status

Working1

270 (91.84%)

250 (85.03%)

520 (88.44%)

Ambulatory2

22 (7.48%)

43 (14.63%)

65 (11.05%)

Bedridden3

2 (0.68%)

1 (0.34%)

3 (0.51%)

OI treatment other than INH (n = 584)

Given4

143 (49.14%)

124 (42.32%)

267 (45.72%)

Not given

148 (50.86%)

169 (57.68%)

317 (54.28%)

Hemoglobin level (n = 532)

<=10 mg/dl

16 (5.90%)

19 (7.28%)

35 (6.58%)

>10 mg/dl

255 (94.10%)

242 (92.72%)

497 (93.42%)

CD 4 cells count (cells/μl) (n = 585)

<350

84 (28.77%)

69 (23.55%)

153 (26.15%)

350 – 499

121 (41.44%)

116 (39.59%)

237 (40.51%)

> = 500

87 (29.79%)

108 (36.86%)

195 (33.33%)

Weight (kg)

<40

3 (1.02%)

13 (4.42%)

16 (2.72%)

40-49

81 (27.55%)

87 (29.59%)

168 (28.57%)

50-60

117 (39.63%)

129 (43.88%)

246 (41.84%)

>60

93 (31.63%)

65 (22.11%)

158 (26.87%)

Follow-up outcome

Alive

181 (61.56%)

105 (35.71%)

286 (48.64%)

Lost to follow up

66 (22.45%)

109 (37.07%)

175 (29.76%)

Entry to ART

20 (6.8%)

19 (6.46%)

39 (6.63%)

TB

13 (4.42%)

36 (12.24%)

49 (8.83%)

 

Other5

14 (4.76%)

25 (8.50%)

39 (6.63%)

Median CD 4 cells count (cells/μl)

 

415 (IQR 328–786)

444 (IQR 357–613)

422 (IQR 344–589)

  1. 1Working: able to perform usual work in and out of the house.
  2. 2Ambulatory: able to perform activities for daily living.
  3. 3Bedridden: unable to perform activities for daily living.
  4. 4Cotrimoxazole, Fluconazole.
  5. 5Transferred out and dead.